Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – Stock analysts at Jefferies Group dropped their Q3 2017 earnings estimates for shares of Bellicum Pharmaceuticals in a research note issued on Tuesday. Jefferies Group analyst B. Amin now anticipates that the biopharmaceutical company will earn ($0.74) per share for the quarter, down from their prior forecast of ($0.63). Jefferies Group has a “Buy” rating and a $16.00 price target on the stock. Jefferies Group also issued estimates for Bellicum Pharmaceuticals’ Q4 2017 earnings at ($0.74) EPS, FY2017 earnings at ($3.02) EPS, FY2018 earnings at ($2.68) EPS, FY2019 earnings at ($3.02) EPS, FY2020 earnings at ($1.20) EPS and FY2021 earnings at ($0.04) EPS.

BLCM has been the topic of several other reports. BidaskClub cut shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Cantor Fitzgerald set a $32.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 24th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Ladenburg Thalmann Financial Services set a $31.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 24th. Finally, Raymond James Financial, Inc. set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $26.20.

COPYRIGHT VIOLATION WARNING: “Brokers Offer Predictions for Bellicum Pharmaceuticals, Inc.’s Q3 2017 Earnings (BLCM)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/11/brokers-offer-predictions-for-bellicum-pharmaceuticals-inc-s-q3-2017-earnings-blcm.html.

Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 7.65 on Friday. The firm’s market capitalization is $254.18 million. The firm has a 50-day moving average of $11.55 and a 200 day moving average of $12.35. Bellicum Pharmaceuticals has a 12-month low of $7.59 and a 12-month high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter last year, the business earned ($0.61) earnings per share.

Large investors have recently added to or reduced their stakes in the company. Knott David M bought a new stake in Bellicum Pharmaceuticals during the first quarter valued at about $131,000. Fox Run Management L.L.C. bought a new stake in Bellicum Pharmaceuticals during the first quarter valued at about $171,000. Monashee Investment Management LLC bought a new stake in Bellicum Pharmaceuticals during the first quarter valued at about $1,974,000. Dynamic Technology Lab Private Ltd bought a new stake in Bellicum Pharmaceuticals during the first quarter valued at about $277,000. Finally, LMR Partners LLP bought a new stake in Bellicum Pharmaceuticals during the first quarter valued at about $3,339,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

In related news, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now directly owns 14,314 shares of the company’s stock, valued at $175,489.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alan A. Musso sold 6,311 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total transaction of $77,246.64. The disclosure for this sale can be found here. Insiders sold 30,571 shares of company stock worth $367,295 over the last three months. Corporate insiders own 23.30% of the company’s stock.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.